Glenmark Pharmaceuticals Ltd vs Valiant Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2154 as of 11 Jun 14:45 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Valiant Laboratories Ltd changed from 2080 on March 2024 to 0 on March 2025 . This represents a CAGR of -100.00% over 2 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Valiant Laboratories Ltd changed from ₹ 632.63 crore on March 2024 to ₹ 333.65 crore on March 2025 . This represents a CAGR of -27.38% over 2 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 3959 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the growth of 0.37% The revenue of Valiant Laboratories Ltd for the Mar '26 is ₹ 92.15 crore as compare to the Dec '25 revenue of ₹ 53.09 crore. This represent the growth of 73.57% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 578.28 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -20.77% The ebitda of Valiant Laboratories Ltd for the Mar '26 is ₹ 4.98 crore as compare to the Dec '25 ebitda of ₹ -0.26 crore. This represent the decline of -2015% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 301.32 crore over 8 quarters. This represents a CAGR of -5.89% The net profit of Valiant Laboratories Ltd changed from ₹ -0.51 crore to ₹ 1.76 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Valiant Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Valiant Laboratories Ltd

Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s.
Bharat Chemicals' through deed of partnership dated October 17, 1980.
The said Partnership Firm, M/s.
Bharat Chemicals thereafter converted into a Public Company to 'Valiant Laboratories Limited' via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies. The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol.
The Company gradually, commenced manufacturing of Paracetamol by late 1982.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Valiant Laboratories Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 60,506 Cr while Market cap of Valiant Laboratories Ltd is 380 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd?

As of June 11, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2144.1. On the other hand, Valiant Laboratories Ltd stock price is INR ₹70.0.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Valiant Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.